Can ofloxacin (a fluoroquinolone antibiotic) cause hemolytic jaundice?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Ofloxacin Cause Hemolytic Jaundice?

Yes, ofloxacin can cause hemolytic jaundice, though this is a rare but serious adverse event. The FDA drug label explicitly lists hemolytic anemia among the postmarketing adverse events for ofloxacin, and case reports document fluoroquinolone-induced hemolysis leading to jaundice 1.

Evidence from Drug Labeling

The FDA-approved ofloxacin label clearly identifies hemolytic anemia as a postmarketing adverse event, specifically noting "anemia, including hemolytic and aplastic" among hematopoietic complications 1. The label also warns that serious and sometimes fatal events may include "anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura" and explicitly states that "hepatic dysfunction including: hepatic necrosis, jaundice (cholestatic or hepatocellular), hepatitis" can occur 1.

The drug label mandates immediate discontinuation at the first appearance of jaundice or signs of hypersensitivity 1.

Mechanism and Clinical Presentation

Fluoroquinolone-induced hemolysis appears to be immune-mediated. A documented case of ofloxacin-induced hemolysis in a G6PD-deficient patient resulted in pigment nephropathy, presenting with the classic triad of acute kidney injury, jaundice, and hemolysis 2. Related fluoroquinolones show similar patterns:

  • Levofloxacin (closely related to ofloxacin) has caused autoimmune hemolytic anemia with severe jaundice, with patients presenting with hemoglobin drops to 5-6.7 g/dL, positive direct Coombs test, indirect bilirubin of 5.5 mg/dL, and markedly elevated LDH 3, 4
  • Temafloxacin was withdrawn from the market in 1992 specifically due to immune-mediated hemolytic anemia (95 cases documented) 4, 5
  • Ciprofloxacin has 12 published cases of hemolytic anemia 4

High-Risk Populations

G6PD deficiency is a critical risk factor. While ofloxacin is not traditionally listed among unsafe drugs in G6PD deficiency, case reports demonstrate it can trigger severe intravascular hemolysis in these patients 2. The immune checkpoint inhibitor guideline specifically lists fluoroquinolones (including ciprofloxacin and ofloxacin) among drugs requiring evaluation when hemolysis occurs 6.

Clinical Recognition and Management

When hemolytic jaundice occurs with ofloxacin:

  1. Immediate discontinuation of ofloxacin is essential 1, 3, 4

  2. Laboratory confirmation should include:

    • Complete blood count with evidence of anemia and hemolysis on peripheral smear
    • LDH, haptoglobin, bilirubin (indirect), reticulocyte count
    • Direct antiglobulin test (Coombs)
    • G6PD level 6, 2

  3. Supportive treatment may require:

    • Packed red blood cell transfusions
    • Corticosteroids (prednisone) for immune-mediated cases
    • Management of complications including acute kidney injury from pigment nephropathy 2, 3, 4

  4. Recovery timeline: Hematologic recovery typically occurs within days to weeks after drug discontinuation 3, 4

Critical Caveat

Cross-reactivity exists among fluoroquinolones. Patients who develop hemolytic anemia with one fluoroquinolone should not receive any other fluoroquinolone, as antibodies may cross-react 4, 5. One case demonstrated quinine-dependent antibodies in a patient with temafloxacin-induced hemolysis, suggesting structural similarities may trigger cross-reactions 5.

Practical Implications

While hemolytic jaundice from ofloxacin is rare, clinicians must maintain high suspicion when patients develop jaundice, fatigue, or dark urine during or shortly after ofloxacin therapy. The condition can be life-threatening but is reversible with prompt recognition and drug discontinuation. Screen for G6PD deficiency in high-risk populations before prescribing ofloxacin, and avoid all fluoroquinolones in patients with prior fluoroquinolone-associated hemolysis.

References

3
Research

Autoimmune hemolytic anemia induced by levofloxacin.

Case reports in infectious diseases, 2014

4
Research

Levofloxacin-induced autoimmune hemolytic anemia.

The Annals of pharmacotherapy, 2003

Related Questions

In a newborn with early‑onset severe jaundice, anemia (hemoglobin 91 g/L) and reticulocytosis (7 %), what is the most appropriate next investigation?
In a 49-year-old woman with a CBC showing mild normocytic anemia (RBC 4.07 M/µL, hemoglobin 12.1 g/dL, MCV 92.7 fL), what is the likely cause and what further evaluation and treatment should be pursued?
In a 16‑year‑old female with acute gastroenteritis, severe anemia (hemoglobin 7 g/dL), leukopenia, elevated serum iron, markedly increased ferritin, low total iron‑binding capacity, decreased complement C3 and C4, elevated total and direct bilirubin, elevated lactate dehydrogenase, and a peripheral smear showing normocytic normochromic red cells with macrocytes, what is the appropriate treatment?
What is the diagnosis and recommended treatment for a 43‑year‑old obese male with chronic right mid‑to‑lower abdominal pain, mild unconjugated hyperbilirubinemia, positive hepatitis A IgG, and a mildly elevated reticulocyte count, given normal liver imaging and laboratory studies?
What laboratory tests should be ordered for a 21‑year‑old female with a history of anemia who experienced a 2‑minute syncopal episode?
Does arterial blood pressure increase in cardiogenic shock?
What is the likely cause and emergent management of a patient with sudden severe headache, dizziness, bilateral weakness, and clammy sweating, with a normal electrocardiogram (ECG) and normal blood glucose?
How does chronic kidney disease impact a pilot's ability to obtain and retain medical certification, and what monitoring and restrictions are required at different stages of renal impairment?
Two days after dialysis, the patient’s serum sodium is 139 mmol/L and serum chloride is 88 mmol/L; what is the significance of these values and how should the metabolic alkalosis be evaluated and managed?
What is the normal diameter of the main pulmonary artery on transthoracic echocardiography?
How should a post‑dialysis serum sodium of 129 mmol/L and chloride of 88 mmol/L be interpreted and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.